phylogeny of rickettsiales rrs - travel medicine...rickettsiaceae anaplasmataceae neoehrlichia...

Diagnosis and empirical treatment of suspected rickettsial infections

J. Stephen Dumler, M.D.

Professor and Chairperson

Integrated Departments of Pathology

Uniformed Services University, Walter Reed National Military Medical Center, and the Joint Pathology Center

Bethesda, MD

Disclosures

Funding• National Institutes of Allergy and Infectious Diseases (R01AI044102)• PAT-74-3977 Uniformed Services University of the Health Sciences• CDMRP Tick-borne Disease Research Program (W81XWH-17-1-0668)• CDMRP Tick-borne Disease Research Program (TB180110)• Global Emerging Infections Surveillance / Armed Forces Health Surveillance Branch

(P0019_17_HS)

The opinions expressed herein are those of the author(s) and are not necessarily representative of those of the Uniformed Services University of the Health Sciences (USUHS), the Department of Defense (DOD); or, the United States Army, Navy, or Air Force.

Phylogeny of Rickettsiales (rrs)

0.1

O tsutsugamushi

E coli

C burnetii

B bacilliformisB henselae

B quintana

N sennetsu

W pipientis

A phagocytophilum

E chaffeensis E ewingii

R typhi

R prowazekii

R felis

R australisR akari

R honeiR rickettsii

R parkeriR conorii

R sibiricaR africae

α‐proteobacteria

γ‐proteobacteria

RickettsiaceaeAnaplasmataceae

Neoehrlichia mikurensis

E muris

1 2

3 4

5 6

Rickettsial diseases:The genera Rickettsia, Ehrlichia, and Anaplasma

• obligate intracellular bacteria

• Rickettsia and Orientia

• cytoplasmic

• Ehrlichia and Anaplasma

• vacuolar

• contain DNA, RNA, ribosomes

• divide by binary fission

• Gram-negative cell wall

• genomes with typical bacterial genes

• lack genes for glycolysis

• genes for transmembrane transport e.g. ATP, amino acids

Pathogenesis of vasculotropic rickettsioses

Rickettsiaendothelial cells

endosome escape osmotic injury

spread

Rickettsia spp. with Standing in Nomenclature species group vector human pathogenicity diseaseRickettsia africae spotted fever tick yes African tick bite feverRickettsia conorii spotted fever tick yes Mediterranean spotted feverRickettsia heilongjiangensis spotted fever tick yes Far Eastern tick‐borne rickettsiosisRickettsia honei spotted fever tick yes Flinders Island spotted fever; Thai tick typhusRickettsia japonica spotted fever tick yes Japanese spotted feverRickettsia massiliae spotted fever tick yes R. massiliae spotted feverRickettsia parkeri spotted fever tick yes R. parkeri rickettsiosis; Maculatum diseaseRickettsia raoultii spotted fever tick yes scalp eschar and neck lymphadenopathyRickettsia rickettsii spotted fever tick yes Rocky Mountain spotted feverRickettsia sibirica spotted fever tick yes Siberian tick typhusRickettsia slovaca spotted fever tick yes scalp eschar and neck lymphadenopathyRickettsia australis transitional tick yes Queensland tick typhusRickettsia aeschlimannii spotted fever tick potentialRickettsia helvetica spotted fever tick potentialRickettsia montanensis spotted fever tick potentialRickettsia peacockii spotted fever tick potentialRickettsia rhipicephali spotted fever tick potentialRickettsia tamurae spotted fever tick potentialRickettsia hoogstraalii transitional tick potentialRickettsia canadensis ancestral tick potentialRickettsia amblyommatis spotted fever tick unknownRickettsia asiatica spotted fever tick unknownRickettsia buchneri spotted fever tick unknownRickettsia bellii ancestral tick unknownRickettsia akari transitional mite yes rickettsialpoxRickettsia prowazekii typhus louse yes epidemic (louse‐borne) typhusRickettsia asembonensis transitional flea unknownRickettsia felis transitional flea yes flea‐borne spotted feverRickettsia typhi typhus flea yes murine (endemic or flea‐borne) typhus

Spotted fever group rickettsioses

Typhus fever group rickettsioses Orientia

7 8

9 10

11 12

Febrile illness in Southern Sri Lanka, March ‐ October, 2007

Infection / Disease no. testedno. with serologic

evidence% with acute infection

bacteremia/sepsis 1091 11 1.0%

HIV 1079 0 0%

leptospirosis 889 120 13.5%

dengue (serotypes 2,3,4) 859 54 6.3%

any rickettsial infection

883

156 17.7%

scrub typhus 9 2.7%

spotted fever group rickettsiosis 86 9.7%

typhus group rickettsiosis 29 3.3%

indeterminate 32 3.6%

Q fever 889 13 1.5%

TOTAL 883‐1091 354 37.3%

Reller ME, et al . Emerg Infect Dis. 2011; 17:1678-84; Reller ME, et al. Emerg Infect Dis. 2012; 18:256-63; Reller ME, et al. Emerg Infect Dis. 2012; 18:825-9.

Febrile illness in Southern Sri Lanka; March ‐ October, 2007

Infection / Disease no. testedno. with serologic

evidence% with acute infection

% initial dxcorrect

bacteremia/sepsis 1091 11 1.0%

HIV 1079 0 0%

leptospirosis 889 120 13.5% 23%

dengue (serotypes 2,3,4) 859 54 6.3% 14%

any rickettsial infection

883

156 17.7%

0%

scrub typhus 9 2.7%

spotted fever group rickettsiosis 86 9.7%

typhus group rickettsiosis 29 3.3%

indeterminate 32 3.6%

Q fever 889 13 1.5% 0%

TOTAL 883‐1091 354 37.3% 37%Reller ME, et al . Emerg Infect Dis. 2011; 17:1678-84; Reller ME, et al. Emerg Infect Dis. 2012; 18:256-63; Reller ME, et al. Emerg Infect Dis. 2012; 18:825-9.

Etiology of Severe Febrile Illness in Low‐ and Middle‐Income Countries: A Systematic ReviewPLoS One. 2015; 10: e0127962.

Percent of febrile patients as confirmed cases according to region and age in all eligible studies, 1980–2013

East Africa

North Africa*

West Africa

South Central Asia

South East Asia

West Asia*

PediatricAll Regions

All Regions

Rickettsial infections 7.4 4.9 6.6 2.3 3.3 4.9

Spotted fever group 8 3.8 7.4 6.8

Typhus group 0.4 1.1 6.6 2.3 1.9 3.3

Scrub typhus 4.9 8 8 7.8

* None tested

Case 1 - 8y boy from suburban Atlanta• 2 wk PTA - mild respiratory sx, low fever, vague rash - proventil,

steroids, amoxicillin, quell• 2 d PTA - fever, rash - augmentin, deltasone, albuterol• unresponsive - plt 19K, Na 130, BUN 45, creat 1.2, AST 237, ALT

152• diffuse cerebral edema - herniation, death• Post-mortem examination performed

Case 1. 8y boy from suburban Atlanta

R. rickettsii serology<64

ImmunohistochemistryFor R. rickettsii +

Final dx: RMSF

lung

kidney

Clinical manifestations of spotted fever rickettsioses: RMSF

fever, headache, myalgias, rash

rash - macular, maculopapular, petechial

gastrointestinal system

renal system acute tubular necrosis 2 to hypotension

shock and multi-organ failure

cardiopulmonary system non-cardiogenic pulmonary edema

central nervous system –meningoencephalitis cerebral edema, herniation

skin lung

brain

13 14

15 16

17 18

Skin rash in RMSF

macularmacular maculopapularmaculopapular

petechialpetechial

ecchymosisecchymosis

Frequent clinical features of rickettisoses(meta analysis median percentages of patients with clinical feature)

History, signs, or symptoms R. rickettsiiRMSF

R. prowazekiityphus

R. typhimurine typhus R. conorii MSF

Fever 100 100 100 100

Headache 91 100 75 70

Myalgia 72 70 50 58

Rash 90 32 45 98

Rash on palms and soles 82 na* 2 79

Nausea or vomiting 60 45 46 36

Abdominal pain 43 65 18 na

Conjunctivitis 30 34 33 36

Pneumonitis 15 8 7 10Any severe neurologic complication 26 50 1 11

na* data not available

Laboratory abnormalities in ehrlichiosis (%)

Laboratory finding RMSF HME HGA

White blood cell count

> 10,000/L 28 1 1

< 5,000/L 66 49

> 10% bands 69 76

Platelet count/L

< 150,000 52 72 71

Serum sodium < 132 mEq/L 56

ALT or AST 2x normal value 62 76 71

Cerebrospinal fluid

Pleocytosismononuclear cell predominanceneutrophil predominance

484650

606733

rare

Glucose 50 mg/dL 8 14

Protein 50 mg/dL 35 44

Opening pressure 250 mm H2O 14

Rocky Mountain spotted feverdiagnosis and risk

risk of death 5 x in patients after day 5 of illness

most patients are initially examined before day 5, but not treated until after day 5

major factors for ineffective diagnosis and delayed therapy:- absence of typical rash- presentation during non-peak tick activity season- presentation during first 3 days of illness

Demographics of SFG rickettsiosis cases by hospitalization status and fatal

outcome, 2008–2012 (CRFs)n (HR, %) RR n (CFR, %) RR

GenderMale 1,474 (28) – 17 (0.3) –Female 711 (24) 1.2 19 (0.6) 2.0

Age group (years)

< 10 131 (29) 1.0 8 (1.6) 7.710–19 140 (21) 0.8 2 (0.3) 1.420–29 174 (23) 0.8 1 (0.1) 0.630–39 229 (23) 0.8 1 (0.1) 0.540–49 302 (22) 0.8 7 (0.5) 2.450–59 376 (24) 0.9 6 (0.4) 1.860–69 401 (28) – 3 (0.2) –70+ 399 (40) 1.4 6 (0.6) 3.0

RaceWhite 1,674 (27) – 23 (0.4) –Black 118 (44) 1.7 1 (0.4) 1.1American Indian/Alaska Native 67 (34) 1.3 7 (2.0) 5.4Asian/Pacific Islander 19 (41) 1.5 1 (2.0) 5.7

Ethnicity

Hispanic 104 (34) 1.4 4 (1.3) 3.2Non‐Hispanic 1,570 (26) – 25 (0.4) –

Immune status

Immunocompromised 205 (50) 2.0 7 (1.7) 4.4Not immunocompromised 1,066 (25) – 17 (0.4) –

Life‐threatening complications

One or more 241 (79) 11.7 17 (6.0) 27.9

None 1,949 (24) – 19 (0.2) –

Case 2 - 67 year old physician from Maryland• Traveled to Argentina and Brazil (6 weeks ago)• Traveled to Kenya and South Africa (returned 4d ago)

• safari• walked in/along ocean and brackish rivers• drank local water• exposed to feral dogs and cats• ate partially cooked meats

• Returned to US with fever (38.5C), headache, confusion for 24h, 20-30 petechiae on both calves; two eschars on right thigh

• WBC 3.9 x 109/L; platelets 210 x 109/L• Acute phase serology for viruses and rickettsiae negative; malaria

smear neg.• Skin biopsy performed

19 20

21 22

23 24

Case 2 ‐ 67 year old physician from Maryland who traveled to Argentina, Brazil, Kenya, and South Africa

Convalescent spotted fever group antibody titer ‐ 2560

Eschar biopsy

IHC for spotted fever group rickettsiae

Diagnosis: African tick bite fever

(R. africae or R. conorii)


History, signs, or symptoms R. rickettsiiRMSF R. conorii MSF R. typhi

murine typhus R. conorii MSF

Fever 100 100 100 100

Headache 91 70 75 70

Myalgia 72 58 50 58

Rash 90 98 45 98

Rash on palms and soles 82 79 2 79


Abdominal pain 43 na 18 na


Pneumonitis 15 10 7 10

Any severe neurologic complication 26 11 1 11


Laboratory abnormalities in rickettsioses

Laboratory finding

(% of cases with finding)

Rocky Mountain spotted fever

Mediterranean spotted fever

Epidemic typhus



> 10,000/L 28 28 14 28

<5,000/L 20 3 20

> 10% bands 69

Platelet count/L

< 150,000 52 35 43 35

Serum sodium < 132 mEq/L 56 25 25

Elevated ALT or AST 62 39 63 39

Cerebrospinal fluid


484650

present 21 present

Glucose 50 mg/dL 8

Protein 50 mg/dL 35


0

20

40

60

80

100

% of patients with finding

Comparison of clinical findings in various spotted fever rickettsioses

Eschars and skin lesions with SFGR

African tick‐bite fever–multiple eschars African tick‐bite fever ‐ vesicles

Rickettsialpox ‐ eschar Rickettsialpox ‐ vesicles

TIBOLA or DEBONEL TIBOLA or DEBONEL

MSF – tache noire Japanese SF ‐ eschar R. parkeri ‐ eschar

Rickettsial infection in travelers to Sub-Saharan Africa• GeoSentinel Surveillance Network 2007

2,451 travelers with fever• 21% malaria• 2% rickettsia• 22% undiagnosed

• GeoSentinel Surveillance Network 2009• 280 travelers with rickettsial infection

• 231 (82.5%) had spotted fever (SFG) rickettsiosis• 16 (5.7%) scrub typhus• 10 (3.6%) typhus group (TG) rickettsiosis• 4 (1.4%) indeterminable SFG/TG rickettsiosis• 1 (0.4%) human granulocytic anaplasmosis

• Swedish travelers 1997-2001• 77 cases• risk 4-5 x malaria risk in same region

• 152 first time Norwegian travelers to Sub-Saharan Africa• 9% seropositive• 62% of seropositives symptomatic

• 940 Norwegian travelers followed prospectively• 4 to 5% overall• 27% of those flu-like illnesses

25 26

27 28

29 30

Case 3 - 4 year old Hispanic boy with sudden onset fever• Lives in McAllen TX, but travels often to Mexico to visit family• Physical exam

• T 40.0C• generalized petechial rash (day 2)• Vomiting and diarrhea (day 6)

• WBC 2.9 x 109/L (7% bands), platelets 51 x 109/L, Hct 30.1%, Na+

132 meq/L, ALT 102 U/L• Started amoxicilin, then cefotaxime• All blood, urine, stool cultures and O&P exams negative

Case 3 - 4 year old Hispanic boy with sudden onset fever from South Texas who travels to Mexico

• CXR Bilateral interstitial infiltrates• Required PICU management:

• 13 units platelets• 1 unit FFP over 3 days

• Acute phase serum• Day 1: Weil-Felix OX19 160, OX2 160, OXK 40• Day 4: Weil-Felix OX19 320

• Treated with doxycycline• Convalescent serum R. typhi titer 8192


History, signs, or symptoms R. rickettsii RMSF R. conorii MSF R. typhimurine typhus

R. prowazekiityphus

Fever 100 100 100 100

Headache 91 70 75 100

Myalgia 72 58 50 70

Rash 90 98 45 32

Rash on palms and soles 82 79 2 na*


Abdominal pain 43 na 18 65


Pneumonitis 15 10 7 8Any severe neurologic complication 26 11 1 50


Laboratory abnormalities in rickettsioses

Laboratory finding

(% of cases with finding)

Rocky Mountain spotted fever


Murine typhus

Epidemic typhus


> 10,000/L 28 28 30 14

<5,000/L 20 28 3

> 10% bands 69

Platelet count/L

< 150,000 52 35 48 43

Serum sodium < 132 mEq/L 56 25 50

Elevated ALT or AST 62 39 50 63

Cerebrospinal fluid


484650

present21

1000

21

Glucose 50 mg/dL 8 0

Protein 50 mg/dL 35 (sl )


Murine typhus ecologySylvatic/suburbanurban

Rat flea (Xenopsylla cheopis)

Rattus spp.

Cat flea (Ctenocephalides felis)

Didelphus virginianus

31 32

33 34

35 36

Case 4 - 51 year old business executive from Minnesota• Recreational travel to Thailand near Burmese border

• walked through rugged, hilly country

• Returned to St. Paul, MN 8-12 days later• Within 1 week

• fever (40.6C), headache, confusion, eschar on left scapula• bilateral CN IV palsy, facial diplegia, bilateral evoked nystagmus; motor 0/5 lower extremeties;

DTR 3+ symmetrical

• WBC 14 x 109/L; platelets 115 x 109/L; ALT 462 U/L; CSF – 25 WBC/μL, protein 49 mg/dL, glucose 57 mg/dL

• Illness progressed rapidly• ARDS requiring prolonged ventilation and tracheostomy• Renal failure requiring hemodialysis• Coma

• Blood cultures negative• JE and dengue antibodies negative• malaria smear neg.

Case 4- 51 year old business executive from Minnesota with recreational travel to Thailand near Burmese border

• Convalescent serum rickettsia serologic results• Spotted fever group rickettsiae (R. rickettsii) <64• Typhus group rickettsiae (R. typhi) <64• Scrub typhus (Orientia tsutsugamushi) 10,240

• 6 month follow-up• Stable, partially blind, nerve deafness, significant cognitive

deficits, gait ataxia

• Diagnosis: Scrub typhus

Scrub typhus

• Orientia tsutsugamushi

• transmitted by larval trombiculid mites (chiggers)

• febrile illness

• 50% with eschar

• > 1 billion at risk

• 1 million infections/year

http://www.mikebaker.com/animals/chiggers.html

Frequent clinical features of undifferentiated febrile illnesses(meta analysis median percentages of patients with clinical feature)History, signs, or symptoms spotted fever typhus scrub typhus dengue leptospirosis

Fever 100 100 100 100 100

Headache 82 77 100 78 85

Myalgia 70 45 32 77 77

Rash 94 55 49* 11-53 5

Rash on palms and soles 79 1 na** na na

Nausea or vomiting 54 31 28 53 45

Abdominal pain 33 18 na na 33

Conjunctivitis 21 35 29 na 61

Pneumonitis/cough 11 31 28 35 37

Any severe neurologic complication

17 10 10 1-6 <25

* includes eschars; **na data not available

Laboratory abnormalities in acute undifferentiated febrile diseases

Laboratory finding(% of cases with finding)

spotted fever

typhusscrub typhus

dengue leptospirosis


> 10,000/L 28 22 34 6 39

<5,000/L 24 13 3 25 8

Platelet count/L

< 150,000/μL 44 46 25 59 26

Elevated ALT or AST

50 57 70 64 78

37 38

39 40

41 42

The global expansion of scrub typhus

Differential diagnosis of rickettsial diseases• Viral syndromes and fevers• Human Herpes virus 6 infection• Human parvovirus B19• Enteroviral infection• Epstein-Barr virus infection• Dengue fever• Rubella• Disseminated gonococcal infection• Mycoplasma pneumoniae infection• Leptospirosis• Secondary syphilis• Meningococcemia• Post-group A Streptococcal infections• Typhoid fever• Secondary syphilis• Lyme disease• Rat-bite fever• Toxic shock syndrome

• Rheumatic fever• Hemolytic uremic syndrome• Acute gastrointestinal illness• Acute abdomen• Hepatitis• Hemophagocytic and macrophage activation

syndromes• Kawasaki disease• TTP• ITP• Drug reactions• Immune complex-mediated illness

rickettsiosis diagnosis

• Clinical suspicion most important• Exposure to or known vector bites• Appropriate clinical manifestations

• diagnosis of active infection• skin biopsy with rickettsial antigen demonstration• PCR (blood, buffy coat, eschar swab/biopsy)• culture

• serologic confirmation- not useful during the first 7 to 14 days – need paired sera- IgG vs. IgM- IFA, ELISA, RDT

- routinely unable to distinguish TG from SFG- routinely unable to distinguish among species

- Weil-Felix febrile agglutinins insensitive and nonspecific

Median clinical sensitivity of PCR methods for detection of spotted fever group and typhus group rickettsia in blood and skin/eschar biopsy samples.

Sample rickettsia method no. assays% clinical sensitivity

median (IQR)

all PanRick all 145 23 (15‐34)

SFGR 331 48 (34‐65)

TGR 257 5 (3‐7)

skin all all 233 43 (7‐55)

SFGR 101 67 (55‐79)

TGR 88 6 (5‐6)

blood all all 331 18 (4‐30)

PanRick 101 18 (12‐23)

SFGR 230 42 (24‐56)

TGR 169 3 (2‐10)

all PanRick real‐time PCR 525 7 (4‐23)

SFGR real‐time PCR 123 23 (14‐33)

TGR real‐time PCR 257 5 (3‐7)

SFGR nested PCR 29 31 (31‐31)

SFGR conventional PCR 179 69 (61‐80)

Curr Opin Infect Dis. 2016; 29:433-439

Sensitivity and specificity of serological tests for confirmation of scrub typhus, spotted fever rickettsiosis, and murine typhusDisease* Serological assay Sensitivity Specificity

Scrub typhus IFA IgG 91% 96%

IFA IgM 70‐87% 84‐100%

ELISA IgG 80‐97% 89‐98%

ELISA IgM 84‐100% 73‐99%

ImmChrom IgG RDT 86‐95% 96‐100%

ImmChrom IgM RDT 82 ‐ 94% 86‐100%

Dot EIA 60‐100% 94‐99%

Spotted fever rickettsiosis IFA IgG 85‐100% 99‐100%

IFA IgM 83‐85% 100%

ELISA IgG 83% 87%

ELISA IgM 98% 94%

Murine typhus IFA IgG 83% 93%

IFA IgM 53 ‐ 85% 99%

Kinetics of serological response in RMSF

43 44

45 46

47 48

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1

0.8000 0.5000 0.2000 0.1000 0.0100 0.0010 0.0001

Po

st-t

est

pro

bab

ilit

y

pretest probability (prevalence)

Predictive value of R. rickettsii serology

IgG PPV

IgG NPV

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1

0.8000 0.5000 0.2000 0.1000 0.0100 0.0010 0.0001

Po

st-t

est

pro

bab

ilit

y

pretest probability (prevalence)

Predictive value of R. rickettsii serology

IgG PPV

800,000 500,000 200,000 100,000 10,000 1000 100

pretest probability (cases/million population/year)

Arkansas

Arkansas –fever, headache, rash

Rickettsiosis treatment

• adults: doxycycline, tetracycline• children: doxycycline, tetracycline, chloramphenicol, rifampin?• chloramphenicol associated with excess mortality as compared with

doxycycline or tetracycline when controlled for all other factors• Possibly useful for MSF, other SFG rickettsioses, scrub typhus

• Fluoroquinolones (ciprofloxacin, pefloxacin, ofloxacin)• Macrolides (azithromycin, clarithromycin)

Case 5 – 70 year old woman with MCTD syndrome in Wisconsin• 70y female from Shell Lake, Wisconsin

• History of MCTD syndrome with ANA+; no current medications

• 24h sudden onset fever, rigors, headache, N&V, myalgias

• ED: ill-appearing, T 38.3ºC, no focal physical findings, WBC 10,400, platelets 244,000

• Admitted with increasing fever (T40.0ºC) and transient right-sided seizure; Rx: ceftriaxone without response; blood culture x3 negative

• WBC 6,400, platelets 53,000, peripheral blood smear shown

Case 5 – 70 year old woman with MCTD syndrome in Wisconsin

• Peripheral blood smear: inclusions in ~1% neutrophils and bands

• Peripheral blood PCR + for A. phagocytophilum DNA

• Convalescent serum rickettsia serologic results• E. chaffeensis IgG titer <80• A. phagocytophilum IgG titer 1280

• Diagnosis: human granulocytic anaplasmosis (HGA)

Human Anaplasmataceae infections (human ehrlichiosis)

E. chaffeensis

A. phagocytophilum

E. ewingii

• Human monocytic ehrlichiosis (HME) - Ehrlichia chaffeensis

• Human granulocytic anaplasmosis (HGA) - Anaplasma phagocytophilum

• Other human ehrlichioses– ehrlichiosis “Ewingii” - caused by E. ewingii, genetically like E.

chaffeensis, phenotypically like HGA

– Ehrlichia muris-like agent ehrlichiosis (Upper Midwest USA)

– Panola Mountain Ehrlichia - genetically similar to Ehrlichia ruminantium (Southeast USA)

– Ehrlichia canis (Venezuela)

– Neoehrlichia mikurensis (Europe and Asia)

– Anaplasma capra (China)

• Ehrlichioses are undifferentiated febrile illnesses with typical laboratory findings.

Pathogenesis of leukocytotropic rickettsiosesphagolysosome fusion

inhibition

49 50

51 52

53 54

Ehrlichia ewingii infection of humans• 82% of patients are immune compromised

• No fatalities have been identified

Ehrlichia muris eauclairensis ehrlichiosis (Upper Midwest USA only)

• 27% of patients are immune compromised

• 23% of patients are hospitalized; no fatalities

Neoehrlichia mikurensis ehrlichiosis (Europe and Asia)

• 15/16 European patients with immune compromise and persistent fever

• > 50% with vascular or thromboembolic events

• 0/7 Chinese patients had immunocompromising conditions

• ≥ 7 subjects (in tick-bite studies) had asymptomatic or very mild infection

Anaplasma capra infection (Asia only)

• 14% with underlying disorders

• 18% of patients are hospitalized, but no fatalities have been identified

The “new” human ehrlichioses…. Geographic distribution of proven and serologically suspected ehrlichiosis and anaplasmosis in humans

Frequent clinical features of ehrlichiosis (meta analysis median % with clinical feature)

History, signs, or symptoms

A. phagocytophilum HGA n=797

E. chaffeensisHME n=464

E. ewingii ehrlichiosis

n=8

E. muriseauclairensis

infectionn=48

CandidatusN. mikurensis

infectionn=23

Anaplasma caprainfection

n=28

Fever 100 97 100 87 78 82

Rash 5 29 0 0 35 25

Headache 82 70 63 66 35 50

Myalgia/arthralgia 73 68 38 69 35/17 14

Nausea 40 57 25 - 22 21

Vomiting 22 43 25 - 22 4Pneumonitis or cough 24 30 0 - 17 4Confusion/ altered MS 17 20 0 - 4 4

Case fatality rate 0.3 1.0 0 deaths 0 deaths 1 death 0 deaths

Table 2. Antibiotic RecommendationsDrug Category Dosage, administration and comments

Doxycycline hyclate effectiveAdults 100 mg orally or intravenously at 12 hour intervalsChildren (<100 lbs.) 4.4 mg/kg/day orally or intravenously in two divided dosesDuration of therapy HME 7-10 days, or at least 3 days after fever has abatedDuration of therapy HGE 10 days

Tetracycline hydrochloride effectiveAdults 500 mg orally in four divided dosesChildren (<100 lbs.) i) 25-50 mg/kg/day orally in two to four divided doses or

ii) 0.6-1.2 g/m2/day in two to four divided doses.

Duration of therapy As for doxycycline hyclate

Rifampin probably effectiveAdults 300 mg orally twice daily.Children (<100 lbs.) 10 mg/kg/day orally twice daily, maximum dose 300 mg eachDuration of therapy Unknown (7-10 days?)

Prevention of RMSF, HME, and HGA in humansprompt tick removaltransmission of A. phagocytophilum may require as little as 4h

No vaccines currently available for humans

Prophylaxis for RMSF contraindicated

Prophylaxis for HME and HGA after tick bite not investigated

Thanks forlistening.Questions?

55 56

57 58

59 60

phylogeny of rickettsiales rrs - travel medicine...rickettsiaceae anaplasmataceae neoehrlichia...

Documents